Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Relmada expects to initiate its Phase 3 program in the first half of 2026
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Subscribe To Our Newsletter & Stay Updated
